E-viri
Recenzirano
-
Niu, Chengu; Zhu, Kaiwen; Zhang, Jing; Joshi, Utsav; Liu, Hongli; Zahid, Salman; Jadhav, Nagesh; Okolo, Patrick I.
International journal of cancer, 1 April 2024, 2024-Apr-01, 2024-04-00, 20240401, Letnik: 154, Številka: 7Journal Article
Immune checkpoint inhibitors are becoming an increasingly common treatment for advanced gastrointestinal cancer, but the possibility of immune‐related adverse events has raised concerns. This study aimed to evaluate the risks of immune‐related adverse events between patients who received immune checkpoint inhibitors and those who received chemotherapy among different types of gastrointestinal cancer. The study utilized data from the multicenter TriNetX database in the United States covering the period between 2015 and 2022. Hazard ratios and 95% confidence intervals were used to describe the relative hazard of immune‐related adverse events based on comparing time‐to‐event rates. Our study revealed that the incidence of immune‐related adverse events was significantly higher in patients who received immune checkpoint inhibitors and chemotherapy compared to those who received chemotherapy only in treating gastrointestinal cancer. CTLA‐4 inhibitors tended to have a higher rate of immune‐related adverse events compared to PD‐1/PD‐L1 inhibitors. Our study found a lower mortality rate among patients who developed immune‐related adverse events compared to those who did not after propensity score matching (HR, 0.661; 95% CI 0.620–0.704; p < .01). We provide important real‐world data on the incidence and impact of immune‐related adverse events in patients with advanced gastrointestinal cancer treated with immune checkpoint inhibitors. Our study's results support clinicians in making informed decisions about the potential benefits and risks of immune checkpoint inhibitor therapy for patients with gastrointestinal cancer. What's new? Immune checkpoint inhibitors are becoming an increasingly common treatment for advanced gastrointestinal cancer, but the possibility of immune‐related adverse events has raised concerns. This large retrospective cohort study confirms the association between immune checkpoint inhibitors and immune‐related adverse events across all gastrointestinal malignancies. CTLA‐4 inhibitors tended to have a higher rate of immune‐related adverse events, and the incidence of events varied depending on the type of gastrointestinal cancer. However, there was a lower mortality rate among patients who developed immune‐related adverse events. The findings could support clinicians in making decisions on immune checkpoint inhibitors therapy in patients with gastrointestinal cancer.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.